3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
10
Myelodysplastic Syndromes
4
Mycoses
4
Hematologic Neoplasms
3
Neoplasms
2
Leukemia
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myeloid
1
Invasive Fungal Infections
1
Glioma
1
Glioblastoma
1
Genetic Predisposition to Disease
1
Candidiasis
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Neoplasms
1
Bone Marrow Failure Disorders
1
Aspergillosis
1
Anemia, Aplastic
1
Interventions
Cyclophosphamide
409
Methotrexate
246
Cytarabine
231
Vincristine
188
fludarabine phosphate
172
Dexamethasone
169
fludarabine
143
Etoposide
143
Peripheral Blood Stem Cell Transplantation
136
Filgrastim
132
Whole-Body Irradiation
116
Mycophenolic Acid
115
Busulfan
112
Doxorubicin
109
Tacrolimus
106
Mercaptopurine
105
Cyclosporine
95
Radiotherapy
93
Melphalan
93
Rituximab
90
pegaspargase
88
Prednisone
84
Asparaginase
84
Daunorubicin
82
Granulocyte Colony-Stimulating Factor
74
blinatumomab
72
Antilymphocyte Serum
71
Calcium Dobesilate
69
Clofarabine
58
Thiotepa
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
posaconazole
×
Clear all
NCT07155226
2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2
Recruiting
84 enrolled